Showing 3251-3260 of 5773 results for "".
- Regenxbio Presents New Data on Investigational AAV Therapeutic for Retinal Conditionshttps://modernod.com/news/regenxbio-presents-new-data-on-investigational-aav-therapeutic-at-aao/2481967/At the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, new data was presented for Regenxbio's ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degener
- Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Gene Therapy for LCA1https://modernod.com/news/atsena-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-gene-therapy-for-lca1/2481966/Atsena Therapeutics announced the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATSN-101, the company’s lead investigational gene therapy for patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). RMAT desi
- First Patient Dosed in Ocugen's Phase 1/2 Trial Evaluating Safety and Efficacy of OCU41OST Modifier Gene Therapy for Stargardt Diseasehttps://modernod.com/news/first-patient-dosed-in-ocugens-phase-12-trial-evaluating-safety-and-efficacy-of-ocu41ost-modifier-gene-therapy-for-stargardt-disease/2481960/Ocugen announced that the first patient has been dosed in its phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. “There is a significant unmet medical need for the approximate 35,000 patien
- Outlook Therapeutics Provides Update on Type A Meetings with FDA for Wet AMD Product Candidatehttps://modernod.com/news/outlook-therapeutics-provides-update-on-type-a-meetings-with-fda-for-wet-amd-product-candidate/2481959/Outlook Therapeutics announced that it has completed the requested Type A Meetings with the FDA to discuss the complete response letter (CRL) dated August 29, 2023 regarding the biologics license application (BLA) for ONS-5010, an investigational ophthalmi
- Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLshttps://modernod.com/news/alcon-canada-launches-clareon-vivity-its-latest-advancement-in-presbyopia-correcting-iols/2481956/Alcon announced that Clareon Vivity, the first and only non-diffractive extended depth of focus (EDOF) IOL on Alcon’s lens platform, is now available in Canada. [1-6] Clareon Vivity is designed to provide high-quality vision from distance to functional near with a visual dist
- Bausch + Lomb Receives CPT Category 1 Code for Xipere from the American Medical Associationhttps://modernod.com/news/bausch-lomb-receives-cpt-category-1-code-for-xipere-from-the-american-medical-association/2481954/Bausch + Lomb announced that the American Medical Association (AMA) has confirmed assignment of the Category 1 Current Procedural Terminology (CPT) code for
- Lumenis’ OptiPlus Dual-Frequency RF Energy Device Launchedhttps://modernod.com/news/lumenis-optiplus-dual-frequency-rf-energy-device-launched/2481949/Lumenis announced the launch of the OptiPlus dual-frequency radiofrequency (RF) device, which is designed to deliver heat across different tissue layers, thus increasing blood circulation to promote medical performance and aesthetic results. According to the company, OptiPlus is a
- Kodiak Reboots Tarcocimab Tedromer Development Program Following Strong Positive Phase 3 DR Resultshttps://modernod.com/news/kodiak-reboots-tarcocimab-tedromer-development-program-following-strong-positive-phase-3-diabetic-retinopathy-results/2481948/Three months after deciding to discontinue tarcocimab tedromer due to two failed late-stage trials, Kodiak Sciences announced it is rebooting its clinical program after its phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to sev
- Kiora’s KIO-301 Molecular Photoswitch Evaluated for Retinitis Pigmentosa in ABACUShttps://modernod.com/news/kioras-kio-301-molecular-photoswitch-evaluated-for-retinitis-pigmentosa-in-abacus/2481946/Kiora Pharmaceuticals announced topline results of a phase 1/2 clinical trial demonstrating proof-of-concept that KIO-301, the company’s first-in-class intravitreal (IVT) molecular photoswitch, has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP)
- Study of Sickle Retinopathy in Children Shows Similar Rate of Occurence as Adultshttps://modernod.com/news/study-of-sickle-retinopathy-in-children-shows-similar-rate-of-occurence-as-adults/2481945/The American Academy of Ophthalmology (AAO) announced the presentations of a study of sickle retinopathy, an age-dependent process that can develop in patients with sickle cell disease, of whom older patients are at substantially higher risk than younger patients. To learn more about ho